Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Adds comments from Regeneron and Amgen in paragraphs 3-4, additional context in paragraphs 5-8
By Blake Brittain
Oct 22 (Reuters) -Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia. Eylea can treat eye diseases like macular degeneration, macular edema and retinopathy.
"We continue to believe that Amgen is infringing our patent rights, and today's decision denying our request for a temporary injunction is not the final word in this litigation," Regeneron said in a statement.
An Amgen spokesperson said that the company will bring its biosimilar, Pavblu, to patients "as quickly as possible to help expand access to affordable and effective treatment."
Biosimilars are versions of biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs are made from living cells and cannot be copied exactly.
The FDA first approved Eylea in 2011. It earned Regeneron $5.89 billion in U.S. sales in 2023.
Tarrytown, N.Y.-based Regeneron sued Thousand Oaks, California-based Amgen for infringing dozens of its patents related to Eylea. A West Virginia federal judge last month rejected Regeneron's request to block Amgen's launch of Pavblu while Regeneron pursues its patent claims against the company in the ongoing case.
Regeneron appealed to the Federal Circuit and asked the court to issue its own block on the Pavblu launch through the appeal. The Federal Circuit rejected the request on Tuesday, allowing Amgen to go forward with the launch.
Reporting by Blake Brittain; Editing by David Bario, Leslie Adler and Lisa Shumaker
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
